Earnings results for Milestone Pharmaceuticals (NASDAQ:MIST)
Milestone Pharmaceuticals Inc. is estimated to report earnings on 11/11/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.49. The reported EPS for the same quarter last year was $-0.52.
Milestone Pharmaceuticals last announced its quarterly earnings results on August 12th, 2020. The reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.02. Milestone Pharmaceuticals has generated ($3.50) earnings per share over the last year. Milestone Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 11th, 2020 based off prior year’s report dates.
Analyst Opinion on Milestone Pharmaceuticals (NASDAQ:MIST)
4 Wall Street analysts have issued ratings and price targets for Milestone Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.25, predicting that the stock has a possible upside of 113.02%. The high price target for MIST is $18.00 and the low price target for MIST is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Milestone Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $13.25, Milestone Pharmaceuticals has a forecasted upside of 113.0% from its current price of $6.22. Milestone Pharmaceuticals has received no research coverage in the past 90 days.
Dividend Strength: Milestone Pharmaceuticals (NASDAQ:MIST)
Milestone Pharmaceuticals does not currently pay a dividend. Milestone Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Milestone Pharmaceuticals (NASDAQ:MIST)
In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock. Only 4.16% of the stock of Milestone Pharmaceuticals is held by insiders. 39.42% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Milestone Pharmaceuticals (NASDAQ:MIST
Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($2.18) to ($2.24) per share. The P/E ratio of Milestone Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Milestone Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Milestone Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here